Sexual function pharmacology: central vs peripheral

It is tempting to lump everything about sexual function into one bucket, but pharmacologically there are at least two distinct things going on, and they live in different places in the body.

The first is desire (libido): the wanting, the motivation, the interest. This is generated in the brain. The second is the physical response: in men, blood flow producing an erection; more broadly, the genital arousal that follows once the brain is engaged. A person can have plenty of desire but a body that does not respond, or a body capable of responding but little interest to begin with. Because these are separate problems, the drugs that address them work in completely different ways, and a drug aimed at one will usually do nothing for the other.

Peripheral drugs act on the body's tissues rather than the brain. The best-known are the PDE5 inhibitors, sildenafil (sold as Viagra) and tadalafil (Cialis). These are small-molecule medicines, not peptides, so you will not find them on this site, but they are the contrast class that makes the central drugs easier to understand.

A PDE5 inhibitor works on the blood vessels in the penis. When a man is sexually aroused, the body releases signals that relax those vessels so blood flows in and produces an erection. PDE5 inhibitors slow the breakdown of one of those signals, so the relaxation lasts longer and the erection is easier to achieve and maintain. The crucial point: they do nothing for desire. Arousal still has to come first. They are plumbing, not wiring, they help the body execute a response the brain has already initiated. For erection problems with a physical cause, this is exactly the right tool, and they are well-studied first-line treatments (see the NHS guidance on erectile dysfunction).

Central agents work the other way round: they act in the brain to influence the wanting rather than the physical machinery. The peptide example is PT-141 (bremelanotide), which works on the [melanocortin receptor system](/topics/melanocortin-receptors), a set of brain pathways involved in sexual motivation, among many other things. Rather than improving blood flow, it nudges the neural circuitry that generates desire.

PT-141 is chemically related to melanotan II, a tanning peptide whose unexpected sexual side effects were what first pointed researchers towards this mechanism. It is sometimes discussed alongside oxytocin, another brain-active molecule linked to bonding and arousal, though as the oxytocin "love hormone" myth explains, that story is far more complicated than the marketing suggests. The key contrast: a central agent can in principle raise interest where there was little, something a blood-flow drug fundamentally cannot do.

PT-141 (bremelanotide) is approved by the US FDA as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, a specific diagnosis of distressing low desire not explained by another condition (the FDA Drugs@FDA record for Vyleesi sets out the indication). That is a narrow, defined use, not a general libido booster, and not an approval for men or for postmenopausal women.

The honest framing matters most here. Neither approach is an aphrodisiac shortcut. Peripheral drugs do nothing for desire and only help when arousal and a treatable physical cause are both present. Central drugs work on complex brain pathways, so effects are modest, variable between people, and far from guaranteed, in the trials the average benefit over placebo was real but small. Both carry side effects: PDE5 inhibitors can cause headaches, flushing and visual changes and interact dangerously with nitrate heart medicines, while bremelanotide commonly causes nausea and can raise blood pressure. Low desire in particular often has psychological, relational or hormonal roots that no single molecule addresses. We grade these claims by human evidence rather than marketing, our methodology explains how.